Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

被引：50

作者：

Morris, Michael J.

De Bono, Johann S.

Chi, Kim N.

Fizazi, Karim

Herrmann, Ken

Rahbar, Kambiz

Tagawa, Scott T.

Nordquist, Luke T.

Vaishampayan, Nitin

El-Haddad, Ghassan

Park, Chandler H.

Beer, Tomasz M.

Perez-Contreras, Wendy J.

Desilvio, Michelle

Kpamegan, Euloge E.

Gericke, Germo

Messmann, Richard Adam

Krause, Bernd J.

Sartor, A. Oliver

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Inst Canc Res, London, England

[3] Royal Marsden Hosp, London, England

[4] British Columbia Canc Agcy, Vancouver, BC, Canada

[5] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France

[6] Univ Hosp Essen, Essen, Germany

[7] Univ Hosp Munster, Munster, Germany

[8] Weill Cornell Med, New York, NY USA

[9] Urol Canc Ctr, Omaha, NE USA

[10] Wayne State Univ, Sch Med, Detroit, MI USA

[11] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA

[12] Norton Canc Inst, Louisville, KY USA

[13] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Rostock Univ, Med Ctr, Rostock, Germany

[17] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 18期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.LBA4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4

引用

页数：2